恒瑞医药：获得多份药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276) announced the approval of clinical trial notifications for multiple drug candidates by the National Medical Products Administration, indicating a significant step forward in its research and development pipeline [1] Group 1: Clinical Trial Approvals - Subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd. received approval for clinical trials of SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Adebali monoclonal antibody injection [1] - Subsidiaries Shandong Shengdi Medicine Co., Ltd. and Shanghai Heng Rui Medicine Co., Ltd. also received approval for clinical trials of HRS-2129 tablets [1]